Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE 2nd, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS. Reardon DA, et al. Among authors: lipp es. J Neurooncol. 2012 Jan;106(2):409-15. doi: 10.1007/s11060-011-0687-1. Epub 2011 Sep 22. J Neurooncol. 2012. PMID: 21938530 Free PMC article. Clinical Trial.
Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.
Reardon DA, Herndon JE 2nd, Peters K, Desjardins A, Coan A, Lou E, Sumrall A, Turner S, Sathornsumetee S, Rich JN, Boulton S, Lipp ES, Friedman HS, Vredenburgh JJ. Reardon DA, et al. Among authors: lipp es. J Neurooncol. 2012 Mar;107(1):213-21. doi: 10.1007/s11060-011-0740-0. Epub 2011 Oct 14. J Neurooncol. 2012. PMID: 21997879 Free PMC article. Clinical Trial.
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.
Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, Keir ST, He J, He Y, McLendon RE, Herndon JE 2nd, Yan H, Bigner DD. Killela PJ, et al. Oncotarget. 2014 Mar 30;5(6):1515-25. doi: 10.18632/oncotarget.1765. Oncotarget. 2014. PMID: 24722048 Free PMC article.
Prognostic marker analysis in pediatric intracranial ependymomas.
McLendon RE, Lipp E, Satterfield D, Ehinger M, Austin A, Fleming D, Perkinson K, Lefaivre M, Zagzag D, Wiener B, Gururangan S, Fuchs H, Friedman HS, Herndon JE 2nd, Healy P. McLendon RE, et al. J Neurooncol. 2015 Apr;122(2):255-61. doi: 10.1007/s11060-014-1711-z. Epub 2015 Jan 7. J Neurooncol. 2015. PMID: 25563815
A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population.
Randazzo DM, McSherry F, Herndon JE 2nd, Affronti ML, Lipp ES, Flahiff C, Miller E, Woodring S, Freeman M, Healy P, Minchew J, Boulton S, Desjardins A, Vlahovic G, Friedman HS, Keir S, Peters KB. Randazzo DM, et al. Among authors: lipp es. J Neurooncol. 2017 Sep;134(2):363-369. doi: 10.1007/s11060-017-2535-4. Epub 2017 Jul 1. J Neurooncol. 2017. PMID: 28669010
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
Ghiaseddin A, Reardon D, Massey W, Mannerino A, Lipp ES, Herndon JE 2nd, McSherry F, Desjardins A, Randazzo D, Friedman HS, Peters KB. Ghiaseddin A, et al. Among authors: lipp es. Oncologist. 2018 Feb;23(2):157-e21. doi: 10.1634/theoncologist.2017-0501. Epub 2017 Nov 13. Oncologist. 2018. PMID: 29133513 Free PMC article. Clinical Trial.
66 results